TCN 202

Drug Profile

TCN 202

Alternative Names: TCN-202

Latest Information Update: 05 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theraclone Sciences
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Simplexvirus glycoprotein B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 05 Jun 2014 Development has been discontinued for Cytomegalovirus infections
  • 11 Sep 2013 Final adverse events data from a phase I trial in Cytomegalovirus infections (in volunteers) presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2013)
  • 10 Sep 2013 Phase-II clinical trials in Cytomegalovirus infections (prevention) in Brazil (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top